TNF inhibitors, including infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab, effectively reduce systemic inflammation, a key driver of atherosclerosis and CVD, and improve outcomes such as reduced risks of myocardial infarction and cerebrovascular events. This evidence concerns the gene TNF and atherosclerosis.